ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vismodegib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2012-11-01

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ.

Br J Clin Pharmacol · comparative study; research-article; clinical trial, phase i; journal article · DOI 10.1111/j.1365-2125.2012.04281.x

Bibliografisk träff 2012-07-17

Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.

Wolfe CM, Green WH, Cognetta AB, Hatfield HK.

Dermatol Surg · journal article; case reports · DOI 10.1111/j.1524-4725.2012.02513.x

Bibliografisk träff 2012-07-01

Vismodegib (Erivedge) for basal cell carcinoma.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2012-07-01

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Keating GM.

Drugs · review; journal article · DOI 10.2165/11209590-000000000-00000

Bibliografisk träff 2012-07-01

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc) · research support, non-u.s. gov't; review; journal article · DOI 10.1358/dot.2012.48.7.1808490

Bibliografisk träff 2012-06-19

Molecular pathways: the hedgehog signaling pathway in cancer.

McMillan R, Matsui W.

Clin Cancer Res · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-2509

Bibliografisk träff 2012-06-07

Vismodegib.

Rudin CM.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1158/1078-0432.ccr-12-0568

Bibliografisk träff 2012-06-01

Vismodegib.

Dlugosz A, Agrawal S, Kirkpatrick P.

Nat Rev Drug Discov · research-article; news · DOI 10.1038/nrd3753

Bibliografisk träff 2012-06-01

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.

N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1056/nejmoa1113713

Bibliografisk träff 2012-06-01

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH.

N Engl J Med · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1113538

Bibliografisk träff 2012-05-01

Ivacaftor, vismodegib, and ingenol mebutate.

Hussar DA, Eckel SP.

J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2012.12517

Bibliografisk träff 2012-02-01

Vismodegib granted FDA approval for treatment of basal cell carcinoma.

Författaruppgift saknas

Oncology (Williston Park) · journal article

Bibliografisk träff 2011-07-13

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA.

Clin Cancer Res · research support, non-u.s. gov't; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-0972

Bibliografisk träff 2011-05-24

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.

Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-11-0975

Bibliografisk träff 2011-05-20

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.

Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE.

Drug Metab Dispos · clinical trial, phase i; journal article · DOI 10.1124/dmd.111.039339